Cullinan Therapeutics Quarterly Cash Flow Statement
NASDAQ: CGEMHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
15.53+0.07 (+0.45%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Cullinan Therapeutics free cash flow
In the quarter ended Jun 30, 2026, Cullinan Therapeutics generated -$38.2 million of operating cash flow. That left free cash flow of -$38.2 million.
Summary generated from market data by MetaCap's automated system. Methodology
Cullinan Therapeutics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -53.70M | -49.66M | -50.71M | -50.61M | -70.06M | -48.50M | -47.65M | -40.56M | -42.03M | -37.34M | -25.56M | -39.18M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 79.00K | 79.00K | 79.00K | 79.00K | 77.00K | 76.00K | 77.00K | 76.00K | 77.00K | 76.00K | 77.00K | 80.00K |
| Stock-Based Compensation | 8.45M | 7.62M | 7.31M | 9.47M | 9.89M | 9.37M | 9.63M | 9.43M | 10.53M | 8.23M | 7.52M | 7.74M |
| Change in Working Capital | 3.30M | 1.00M | -39.00K | 59.00K | 2.58M | 3.46M | -2.07M | 1.90M | -4.74M | 1.63M | -1.75M | -5.35M |
| Operating Cash Flow | -38.22M | -46.05M | -38.11M | -36.88M | -57.61M | -43.16M | -36.63M | -34.14M | -36.29M | -38.25M | -18.13M | -34.14M |
| Capital Expenditures | — | — | -11.00K | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 40.68M | 32.41M | 22.39M | 67.39M | 53.40M | 36.80M | 15.96M | 19.88M | -185.11M | 12.96M | 51.47M | -42.96M |
| Financing Cash Flow | 1.10M | 380.00K | 715.00K | 0 | 373.00K | 0 | 1.58M | 1.32M | 262.20M | 1.08M | 248.00K | 112.00K |
| Net Change in Cash | 3.56M | -13.25M | -15.00M | 30.52M | -3.83M | -6.35M | -19.08M | -12.94M | 40.79M | -24.21M | 33.59M | -76.99M |
| Free Cash Flow | -38.22M | -46.05M | -38.12M | -36.88M | -57.61M | -43.16M | -36.63M | -34.14M | -36.29M | -38.25M | -18.13M | -34.14M |
This table shows 12 quarterly periods of Cullinan Therapeutics's cash flow statement, from Q2 2026 back to Q3 2023, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow CGEM's reporting calendar. What is a cash flow statement?